Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19

Elalfy, Hatem; Besheer, Tarek; El‐Mesery, Ahmed; El‐Gilany, Abdel‐Hady; Soliman, Mahmoud Abdel‐Aziz; Alhawarey, Ahmed; Alegezy, Mohamed; Elhadidy, Tamer; Hewidy, Asem A.; Zaghloul, Hossam; Neamatallah, Mustafa Ahmed Mohamed; Raafat, Douaa; El‐Emshaty, Wafaa M.; Abo El Kheir, Nermin Y.; El‐Bendary, Mahmoud

This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐ and sex‐matched patients on routine supportive treatment. all of them confirmed cases by positive reverse‐transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS‐COV2 from the nasopharynx in a shorter time than symptomatic therapy.